VA
IONS icon

Vident Advisory’s Ionis Pharmaceuticals IONS Stock Holding History

Vident Advisory’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$713K Sell
9,489
-746
-7% -$58.9K 0.01% 1052
2025
Q4 		$810K Sell
10,235
-1,316
-11% -$99.1K 0.01% 911
2025
Q3 		$756K Sell
11,551
-449
-4% -$21.9K 0.01% 968
2025
Q2 		$474K Buy
+12,000
New +$393K 0.01% 1084
2024
Q2 		– Sell
-4,796
Closed -$208K – 1462
2024
Q1 		$208K Sell
4,796
-134
-3% -$6.39K ﹤0.01% 1197
2023
Q4 		$249K Sell
4,930
-656
-12% -$31.4K 0.01% 1105
2023
Q3 		$253K Buy
+5,586
New +$230K 0.01% 1003

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vident Advisory's IONS Position: Q1 2026 in Review

Vident Advisory reduced its Ionis Pharmaceuticals (IONS) stake by 7.3% in Q1 2026, selling an estimated $58.9K and leaving 9,489 shares worth $713K. The position accounts for 0.01% of the portfolio, ranked #1052.

Vident Advisory first reported a position in IONS in Q3 2023 and has held it in 7 quarters since. The position peaked at $810K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Vident Advisory held 9,489 shares of Ionis Pharmaceuticals worth $713K as of Q1 2026.
  • Vident Advisory sold 746 Ionis Pharmaceuticals shares in Q1 2026, an estimated $58.9K.
  • Ionis Pharmaceuticals made up 0.01% of Vident Advisory's portfolio in Q1 2026, its #1052 holding.
  • Vident Advisory first reported a position in Ionis Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
  • Vident Advisory's Ionis Pharmaceuticals position peaked at $810K in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.